Duchenne muscular dystrophy is a rare degenerative condition that causes muscle weakness, loss of movement and eventually death.
Santhera’s proposed treatment, Raxone, aims to treat the respiratory failure associated with the disease, according to the report.
More articles on supply chain:
Why pharmacists can’t speak up when they know customers are overpaying for drugs
Sanofi, Lonza to build $285M biologics facility
Pharma leaders, healthcare experts advocate value-based payments for drugs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
